Acrux Limited (FRA:FJY)

Market Cap	3.23M
Revenue (ttm)	664.32K
Net Income (ttm)	-3.32M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	233
Open	0.0065
Previous Close	0.0060
Day's Range	0.0065 - 0.0065
52-Week Range	0.0020 - 0.0255
Beta	n/a
RSI	51.71
Earnings Date	Nov 25, 2025

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 43
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FJY

Financial Performance

In 2025, Acrux's revenue was 1.19 million, a decrease of -76.63% compared to the previous year's 5.09 million. Losses were -5.95 million, 2.50% more than in 2024.

Financial numbers in AUD